ImmunoGen, Inc. announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer. Ms. Kalofonos joins ImmunoGen from Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research.

She also led all commercial franchises of prescription products. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise - a 2.5 billion dollar business. In this role she oversaw the global blockbuster launch of TAKHZYRO (lanadelumab-flyo).

Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals. Ms. Kalofonos received a BS from Pontificia Universidad Javeriana and an MBA from Babson College.